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In an environment where debates about tertiary care viability 
in South Africa are characterised more by stridency than 
logic, it is refreshing to encounter positive suggestions such 
as those from Kenyon et al.1 They suggested that scrutiny of 
expensive new medications and technologies by a NICE-like 
body would lead to appropriate rationing. NICE refers to the 
UK’s National Institute of Health and Clinical Excellence, a 
government-funded but politically independent body tasked 
with evaluating the clinical efficacy and cost-effectiveness 
of medicines and health devices. Its efficacy in improving 
quality of care and resource allocation is still unclear, and 
similar attempts in the United States have failed because of the 
political sensitivity of perceived rationing in that country.2 The 
proposal to establish a similar unit in South Africa appeared 
unduly optimistic to Taylor,3 who observed correctly that 
setting cost-effectiveness thresholds is not a rationing strategy 
in the absence of a concurrent mechanism and commitment 
to forego established expenditure on other less cost-effective 
items. (This is an issue which has not yet been resolved by 
the United Kingdom’s NICE.) She also observed that cost-
effectiveness analysis is time-consuming, extremely resource-
intensive, and arguably not easy to perform on a large scale in 
South Africa at present.
Further local debate on this matter has been reported 
recently in the Journal of the Colleges of Medicine of South 
Africa, where Price4 argues that there are many more societal 
advantages to tertiary care than those measured by cost per 
patient benefited. His example of society’s assumed willingness 
to pay for the assurance of availability of renal replacement 
therapy highlights the quandary faced by funders – while 
each individual tertiary component may seem a reasonable 
purchase, it is the composite of many such items that proves 
less easy to justify.
The South African Essential Drugs List committee has 
recently started reviewing medication used in the tertiary and 
quaternary setting and, while this venture cannot be equated 
with the depth and complexity of NICE, it has highlighted 
a number of fundamental issues. Attempts to confine 
decision-making to a matrix of efficacy, safety and cost are 
intuitively appealing but raise other problems besides the cost-
effectiveness threshold conundrum; these include historical 
inequities due to the way tertiary care has evolved and is 
structured, societal values that require incorporation, and the 
views of clinicians concerned about restrictions to either scope 
or volume of practice.
The following considerations come to mind:
Tertiary care structure as a barrier to 
collaborative rationing
1.    Collaborative engagement regarding resource allocation 
across disciplines is counter-intuitive – if you help another 
discipline get more funding within a fixed overall budget, 
there’s less left over for yourself. Accommodating clinicians 
who are prepared to forego resources in such situations 
may actually disadvantage their own patients.
2.    Cross-discipline allocative efficiency is hampered by 
the ‘silo effect’ – individual disciplines see little need to 
compare the efficacy and cost of their disciplines with 
others. Comparing an oncologist’s percentage change 
in progression-free survival with a rheumatologist’s 
percentage change in ACR50 is problematic. Resorting 
to cost-utility measures (the whole point of which is to 
provide a common comparator) results in immediate, and 
often valid, protestations that such indices fail to capture 
the subtleties of clinical benefit, or else that the use of these 
measures in a particular field is too immature for such 
comparisons to be fair.
3.    Enthusiasm for new medications and technologies is often 
proportional to marketing push and novelty rather than 
a considered appraisal of true clinical benefit.5 Opinion 
leaders and even august societies may occasionally take 
a stand on a particular medication or technology that is 
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not always borne out by careful review of the underlying 
literature.
4.    The ‘all or nothing’ concept. There may be a level of 
rationing below which function is impossible in some sub-
specialty disciplines such as cardiac transplantation. Units 
that were developed through a combination of need, clinical 
enthusiasm, historical accident and political expediency are 
easy targets for funding cuts. Any further cuts may render 
such units non-viable.
Societal values which may need 
consideration in collaborative rationing
The clinical outputs of health care at a tertiary level are often 
difficult to quantify. At very high levels of expenditure, as in 
the USA, spending at academic medical centres may vary by 
up to 60% without a corresponding measurable improvement 
in outcomes.6 Price’s points about teaching, research and 
international economic attractiveness are well made, but such 
societal values are very difficult or impossible to measure. The 
‘rule of rescue’ is another important consideration. Society may 
have an emotional need to ‘gamble’ resources on vulnerable 
members, such as children with certain malignancies, 
where therapy may not meet conventional criteria of cost-
effectiveness, but where there is a widespread consensus that it 
is still a worthy expenditure.
Arguments other than cost-
effectiveness that are used by clinicians
1.    Academic training – an inability to train to cutting-edge 
First-World standards is seen as a teaching failure. The 
problem is that often the only place where this training can 
be applied is in the private sector or overseas. The corollary 
(to under-train so that clinicians remain in the public sector) 
is deeply concerning.
2.    To be congruent with professional society guidelines 
(often industry-influenced). On occasion, it appears that 
local professional societies have adopted wholesale the 
guidelines of other countries or regions, without regard to 
local exigencies.
3.    Tertiary comprehensiveness: any gaps render the whole 
system incomplete, and the appeal is ‘If we don’t look after 
the patient with this rare illness, then who will?’
4.    Professional autonomy – ‘We should be left to decide the 
scope of practice and appropriate resource needs. Only 
experts in our field can understand it.’ This concept comes 
with the expectation of ability to self-regulate.
5.    The need for tertiary care clinicians to be ‘early adopters’. 
This carries the risk that implementing technologies with an 
immature evidence base sometimes causes more harm than 
good. It also creates a problem for funders, who prefer more 
robust evidence of the ratio of benefit to harm.
6.    Older therapies and the ‘grandfather clause’ – rigorous 
evidence of efficacy is historic, unavailable and never likely 
to be found.
7.    ‘It’s about standard of care.’ This may camouflage one of 
two underlying arguments: either ‘It has become accepted 
practice in other countries’ (back to point 4) or ‘We have 
always done it’ (point 6), which begs the question of 
whether there was ever acceptable evidence for the original 
decision.
8.    ‘We have looked into it and it is cost-effective.’ This often 
refers to suboptimally performed cost-minimisation 
exercises.
9.    ‘Failure to get/keep this medication or technology will 
make doctors want to leave.’ Although this is an intuitively 
appealing argument, there’s little evidence that clinicians 
make this sort of decision based on the new non-availability 
of a single item.
10.    ‘Clinicians at X have been using it unrestricted for ages’ 
(issues of interprovincial equity).
Mechanisms of collaborative rationing
Tertiary care is probably too complex for rationing purely 
on the basis of cost-effectiveness to be acceptable to society. 
However, there is clearly a need to counter the perception 
(and occasional reality) that allocated resources are not always 
effectively spent. An attempt by tertiary care to redefine 
itself as an autonomous sector, capable of self-scrutiny and 
unprompted ability to identify and relinquish less effective 
modalities in favour of more effective ones, would probably be 
of interest to both public and private sector financial managers 
with neither the ability nor the inclination to venture into this 
area.
A pragmatic team approach, starting first with a rigorous 
scrutiny of the evidence, not only in terms of quality and 
statistical significance but also in terms of clinical effect 
size, usually allows a defensible judgement call on the 
appropriateness of inclusion of an intervention. This would 
only rarely need to be followed by a formal cost-effectiveness 
review. It may be reasonable to incorporate some or all of the 
arguments mentioned previously as variables in a decision 
matrix, provided that they are applied consistently and 
transparently.
Clinical excellence is about what one does with what one has, 
rather than perseverating about perceived deficiencies. A brief 
consensus document on each diagnostic and therapeutic item 
from a NICE-like body would be valuable in promoting equity 
and in setting an appropriate standard of clinical excellence in a 
resource-constrained environment.
Although limitations on tertiary care budgets are all too real, 
one could argue that optimism, clinical determination and 
credible leadership are equally important (albeit constrained) 
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resources. The desire to preserve the status quo could be 
replaced by optimism about the possibility of building a 
leaner, keener enterprise where it is the norm for resources 
to be allocated on the basis of proven clinical efficacy rather 
than stridency. Determined tertiary clinicians who are aware 
of the absolute benefits of the medications and technologies 
they wish funded would rise to the challenge of maximising 
delivery within a limited budget. The inertia generated among 
undergraduates by disgruntled tertiary physicians affects 
morale, willingness to stay and, most importantly of all, patient 
care. A credible, united, academic leadership could inspire hope 
by finding innovative resource-appropriate African solutions.
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